Abstract RNF115, or Breast Cancer-Associated Gene 2 (BCA2), encodes a RING-finger ubiquitin E3 ligase, expression of which was associated with estrogen receptor (ER)-positive status in human breast tumors. Although the BCA2 promoter contains several estrogen response element (ERE) half-sites, the role of ER in the regulation of BCA2 transcription has not been reported. The aim of this study is to investigate the molecular mechanism by which estrogen regulates BCA2 transcription. BCA2 mRNA and protein levels were examined by RT-PCR and Western blot analysis, respectively, and localization was assessed by immunofluorescence. BCA2 promoter activity in response to E 2 was tested by a dual luciferase reporter assay and ER binding to the BCA2 promoter was examined by chromatin immunoprecipitation assay. We found that BCA2 mRNA and protein levels are regulated by estrogen in ER-positive MCF7 breast cancer cells and MDA MB 231 cells stably transfected with ER. Estrogen treatment in hormonal depleted MCF7 and MDA MB 231/ER stably transfected cells resulted in increased nuclear ER and cytoplasmic and nuclear BCA2 staining. Cycloheximide is not able to inhibit BCA2 mRNA levels, suggesting potential BCA2 regulation at the transcriptional level. Anti-estrogens like tamoxifen and ICI 182 178 counteracted E 2 -induced BCA2 protein and knockdown of ER by ER siRNA resulted in a significant decrease in BCA2 protein and a lower nuclear expression pattern. Estrogen treatment lead to a significant increase in BCA2 promoter response, associated with increased binding of ER to the ERE region of the BCA2 promoter. BCA2 is therefore a newly identified transcriptional target of estrogen receptor.
Introduction
Breast cancer is the second leading cause of cancer-related death in women, comprising about 23 % of all cancers diagnosed worldwide [1] . It has been postulated that longterm exposure to hormones, such as estrogen, contributes to breast cancer development and progression; therefore, understanding the involved molecular mechanism is currently a very attractive area of research. Estrogen hormones play a vital role in the development of both normal and malignant human breast epithelia with estrogen receptor alpha (ERa) being expressed in *70 % of all breast cancers. ER functions as a major regulator of phenotypic properties in estrogen-responsive tumors by controlling transcription of different genes thereby influencing cell proliferation [2] [3] [4] . For example, expression of c-Myc
In memory of Professor Angelika Burger who initiated this project. Professor Burger's research focused on the identification and validation of new molecular targets for the treatment of breast cancer. Dr. Burger's particular interest was in the investigation of the role of the ubiquitin E3 ligase, BCA2, in breast cancer development and to further design and develop small molecular inhibitors targeting BCA2. Dr. Burger was a very gifted researcher, who lost her personal battle with cancer in May, 2011. This article is dedicated to her as a token of our appreciation of a truly outstanding researcher. [5, 6] and cyclin D [7] , two target proteins of estrogen, are sufficient to induce cell cycle progression and cell division [8] . Antiapoptotic genes like EIT-6 and TIT-5 are also direct targets of ligand-mediated ER activity and were shown to promote colony growth in human breast cancer cells [9] . The sequence of events of ER transcriptional activity can be mapped out as follows: ER, a ligand inducible transcription factor, upon binding with 17b-estradiol (E 2 ) changes its conformation, causing dimerization, and subsequently the ER dimer recognizes its cognate regulatory binding sites in the promoter and/or enhancer regions of target genes [10] [11] [12] . Recruitment of ER transcription factor to its response element enables enlisting of co-regulatory proteins, RNA polymerase II, and the basal transcription machinery, leading to the expression of a specific target gene in a single tissue type [13] . ER regulation of target gene expression is complex and involves different mechanisms, including both classical [14] and non-classical pathways [15] . Researchers have recently identified genome wide DNA binding regions of ER by using methods like chromatin immunoprecipitation (ChIP), microarray, and cloning-sequencing strategies [16] . These studies have provided much insight into the mechanism of action of ER and its role in estrogen-related diseases, including breast cancer.
We have previously described Breast Cancer-Associated Gene 2 (BCA2) as a RING-finger ubiquitin E3 ligase, identified from the invasive breast cancer cell line Hs578t by subtractive hybridization and differential display methods and the full length gene was isolated from MDA MB 468 cells [17, 18] . While the BCA2 gene was also identified in ER-negative cells, a large tumor tissue microarray study conducted to examine BCA2 expression in 945 invasive breast cancers indicated that BCA2 expression correlated with clinical variables such as lymph node status, regional recurrence and ER expression pattern [17, 18] . These findings lead us to examine the role of ER in BCA2 expression in the current study.
BCA2 is distributed in the cytoplasm and nucleus and its nuclear presence correlates with ER-positive status (p \ 0.004) [17] . In silico analysis of the BCA2 gene using the TRANSFAC transcription factor binding site database revealed a canonical CAAT box (-737 to -734), reverse TATA box (-656 to -653), and several putative transcription factor binding sites in the promoter region. These include some general transcription factors and nuclear hormone receptors like the ER-binding estrogen response element (ERE) half-sites [17] at positions -129, -493, -1001, and -2407 base pairs upstream from the transcription start site. While BCA2 and ER were found to colocalize in the nucleus, whether or not, and how, ER regulates BCA2 expression and/or activity remains unknown.
To understand the mechanistic basis underlying ER and BCA2 association, in this study we have explored the possibility whether the BCA2 gene can be regulated by ER. Our results show that BCA2 is a transcriptional target of the estrogen-occupied ER. We found that estrogen treatment increased BCA2 mRNA and protein levels, which were inhibited by the 
Western blot assay
Exponentially growing cells were cultured in hormonedepleted media, and total protein was extracted using RIPA buffer, and Western blotting was performed as previously described [18] .
BCA2 promoter luciferase reporter Assay
Cells were plated in 24-well plates and transfected with BCA2 promoter-luciferase vector (Switch Gear Genomics) and renilla vector (Promega). After 24 h, cells were treated with 10 nM E 2 , 100 nM ICI and/or 100 nM Tamoxifen. Luciferase activity was measured using the Dual Luciferase Reporter Assay Kit (Promega) and promoter activity was calculated as relative luciferase units (RLU).
Immunocytochemistry
Cells were treated with 10 nM E 2 for 24 h and ER-specific siRNA for 72 h. Cells were fixed with methanol-acetone and then a primary BCA2 antibody, and a Cy3-conjugated anti-rabbit IgG secondary antibody were used for staining. A pre-diluted anti-mouse ER antibody (Invitrogen) was used as the primary and FITC-conjugated anti-mouse IgG as the secondary antibody.
Chromatin immunoprecipitation assay MCF7 cells were treated with 10 nM estradiol for 12 h. Chromatin immunoprecipitation (ChIP) was performed using a ChIP assay kit (Upstate, Charlottesville, VA) and a ChIPspecific ER antibody (Sc-543, Santa Cruz). Normal rabbit IgG (5lg, Santa Cruz) was used as a control. The EpiTect ChIP qPCR primer assay kit for human RNF115 (NM_014455.2(-) 03Kb: GPH1000795(-)03A was obtained from SABiosciences. These ChIP-qPCR assays are pre-designed and the RT-PCR assays optimized to measure genomic DNA promoter sequence enrichment within ChIP samples. The cycles used were 95°C for 10 min, 40 cycles (95°C, 15 s, 60°C, 60 s). Normalization was done using the percent input method by using 1 % of the starting chromatin as input. A dilution factor of 100 or 6.644 cycles (log2 of 100) is subtracted from the Ct value of the diluted input. All ChIP experiments were run in triplicates and standard errors were calculated.
Results

BCA2 is a breast cancer-related, estrogen-dependent, gene
Previous northern blot analysis suggests that BCA2 mRNA expression is up regulated by estrogen [17] . However, whether or not BCA2 is transcriptionally regulated by ER has not been shown. In this study, we first tested the effect of estrogen on BCA2 gene expression in ER-positive MCF7 breast cancer cells. Cells were grown in hormonedepleted conditions for 48 h and treated with E 2 for different time points. RT-PCR analysis revealed an increase in BCA2 mRNA expression level 6 h after treatment with 10 nM estradiol (E 2 ), which further increased after 24 h (Fig. 1a) . Expression of pS2 mRNA was used as a positive control for E 2 -induced ER transcriptional activity and HPRT as a loading control (Fig. 1a) .
Western blot analysis of these treatment conditions showed that BCA2 protein levels reach a maximum between 6 and 8 h after induction with E 2 (Fig. 1b) .
Furthermore, immunofluorescence analysis showed that when MCF7 cells were grown in hormone-depleted medium, ER is mostly localized to the cytoplasm; however, after treatment with E 2 , nuclear expression levels of ER increased significantly (Fig. 1c) . Also, both ER and BCA2 were found to be localized to the nucleus upon E 2 induction, and a distinct punctuated signal for nuclear BCA2 was observed (Fig. 1c) .
In order to further evaluate E 2 -dependent BCA2 expression, we transfected ER-negative MDA MB 231 cells with ER plasmid, and found that BCA2 mRNA levels were significantly increased in ER-transfected cells, compared to the parental cells/vector control (Fig. 1d) . Immunofluorescence staining of MDA MB 231/ER cells upon E 2 induction also showed increased BCA2 expression in both the cytoplasm and nucleus, similar to that seen in MCF7 cells (Fig. 1e) .
Effect of cycloheximide and anti-estrogens on BCA2 expression
We next tested the effect of cycloheximide (CHX) on E 2 -induced BCA2 expression. The BCA2 mRNA levels were not significantly affected by CHX treatment under the tested conditions (Fig. 2a) , while the mRNA levels of pS2 were decreased, indicating that BCA2 gene expression is primarily regulated by E 2 at the transcriptional level. Our data under the experimental conditions tested suggests that, although pS2 mRNA expression is regulated by estrogen at the transcriptional level [19] , its stability requires de novo protein synthesis. Furthermore, the protein levels of BCA2 were affected by CHX treatment from 12 to 22 h, indicating a half-life greater than 6 h (Fig. 2b) . CHX treatment also had some effect on ER protein level (Fig. 2b) .
To study ER dependency on BCA2 expression, antiestrogens, tamoxifen, and ICI 182 178, were used. Again, E 2 treatment induced levels of ER and BCA2 proteins in MCF7 cells, both of which were inhibited by addition of either tamoxifen or ICI (Fig. 2c) . In this experiment, the basal levels of ER and BCA2 proteins were inhibited by addition of ICI but not Tamoxifen (Fig. 2c) . When MDA MB 231 vector control cells were treated with E 2 , induction of BCA2 protein was observed, which seems to be not inhibitable by the anti estrogen treatments (Fig. 2d) . Slight induction of BCA2 protein was found in MDA MB 231/ER-transfected cells treated with E 2 , which was inhibited by anti-estrogens (Fig. 2d) . Therefore, it appears that anti-estrogens were able to reduce BCA2 protein expression in ER-positive cell lines.
Effect of ER knock down on BCA2 expression levels
To provide direct evidence for the functional role ER has on BCA2 expression, we used small interfering RNAs (siRNAs) to knock down ER in MCF7 cells. A single treatment with ER siRNA decreased ER transcripts within 48 h, and this effect lasted for at least 2 days after single transfection (data not shown). When ER expression was knocked down in MCF7 cells using ER siRNA at concentrations of 30 and 60 nM, BCA2 protein levels were decreased significantly when compared to control treated cells (Fig. 3a) . Immunoflorescence staining of cells treated with ER siRNA also showed lower expression levels of ER and BCA2 (Fig. 3b) . Interestingly, even though BCA2 protein expression predominantly decreased in the ERknockdown cells, its expression was localized near the nuclear membrane region and cytoplasm, with significantly was cloned into a promoterless luciferase plasmid and initial transient transfections were carried out in HEK293T cells along with renilla and ER luciferase plasmids at different ratios of pGL4 promoter to pCDNA3 ER expression vectors to define the optimal levels for luciferase expression. BCA2 promoter activity increased with increasing concentrations of ER (Fig. 4a ) in HEK293T cells and this signal was further increased with E 2 treatments (Fig. 4b) . When these experiments were carried out in MCF7 cells, E 2 treatment only slightly increased BCA2 promoter activity which, however, was completely abolished by tamoxifen co-treatments (Fig. 4c) . The basal levels of the BCA2 promoter activity were also inhibitable by either tamoxifen (Fig. 4c) or ICI (data not shown).
To further define the role of ER in BCA2 transcription, we tested the promoter activity in control vector-and ERstably transfected MDA MB 231 cells in the luciferase reporter assay. The control cell line showed minimal luciferase activity, while the ER-transfected cells exhibited almost a ninefold increase in luciferase signal when compared to the non-promoter controls (Fig. 4d) . Taken together, these data suggest that that both E 2 and ER control BCA2 promoter activity, and consequently the levels of BCA2 mRNA and protein.
ER is recruited to the BCA2 promoter upon E 2 induction
We next performed a ChIP experiment to investigate whether ER is recruited to the BCA2 promoter upon induction with E 2 . The DNA-protein complex was immunoprecipitated using an anti-ER antibody and was then analyzed by quantitative PCR with primers specific for the BCA2 proximal promoter ERE region (Fig. 5a) (Fig. 5b) . Tamoxifen or ICI treatment alone also inhibited the basal levels of ER binding to the BCA2 promoter (Fig. 5b) . These results confirm E 2 -induced recruitment of ER to the BCA2 promoter, supporting our conclusion that ER induces BCA2 expression in ER-positive breast cancer cells.
Discussion
In this study, we have identified BCA2 as a target of ER transcriptional activity in ER-positive breast cancer cells (MCF-7 and MDA MB 231/ER) and have shown that BCA2 gene up-regulation is hormone dependent. We have shown that the BCA2 promoter is activated by hormoneinduced ER, where ER is recruited to the BCA2 promoter ERE half-sites. This study confirms that the up-regulation of BCA2 mRNA and protein expression by hormone is largely due to transcriptional activation. To our knowledge, this is the first report describing hormonal regulation of BCA2 transcription. The conventional model of ER binding suggests that the ER dimer binds to a consensus or pseudopalindromic ERE. Each ER monomer binds to a half-site major groove with a spacer in between and the size of which influences dimer stability, target specificity, and ERE/ER complexation [20] . However, studies have shown that ER can activate transcription of genes containing nonconventional elements like ERE half-sites [14, [21] [22] [23] . There is a vast amount of literature available confirming that ER requires only minimal recognition of some element, a half ERE, for transcriptional activation of a particular gene. The basic structural nature of ER and ERE complexes is dependent on ERE as shown by many protease digestion profiles for different ER/ERE complexes [24] . It is well documented that for a number of genes, the minimal recognition element for transcriptional activation of ER is HERE half ERE (HERE) (5 0 -GGTCA-3 0 ) [25, 26] ; although, there is some controversy over whether ER can bind to an ERE half-site as a homo-dimer [27] [28] [29] or either as a monomer or heterodimer [30] . Studies of ER interaction with the promoter of lactoferin have shown that this promoter contains an SF-1 response element upstream of an imperfect ERE and that one ER dimer binds to this SF-1 response element [31] . Furthermore, the rat prolactin gene promoter binds ER as a homo-dimer to an SF-1 response element and ERE half-site [32] . The DNA foot printing studies of the well-established ER-regulated gene pS2 promoter in MCF7 breast cancer cells showed that it has an imperfect ERE half-site in its promoter [33, 34] . Studies of another widely studied estrogen-responsive gene, progesterone receptor, showed that ER interacts with an ERE half-site located 4 base pairs upstream to the adjacent Sp1 binding sites in its promoter region and that ER can increase its Sp1-DNA binding ability [35] [36] [37] . Thus, a half-site ERE consensus sequence is adequate to bind ER with an affinity sufficient enough for transcriptional activation, suggesting that these simple elements, residing on complex promoters, are able to enhance transcriptional activity with the help of multiple cellular factors and co-activators which function to stabilize ER binding by protein-protein interactions [38, 39] .
Whole genome analysis of transcription factors provided us with an unbiased perspective of their regulatory dynamics. Studies of genome wide analysis of ERa DNA binding sites in the MCF breast cancer cell lines by Lin et.al [40] identified 1,234 high probability binding sites for ER, out of which 94 % were validated by the standard ChIP assays. Of these 94 % validated binding sites, 25 % of them were solely ERE half-motifs. In this study, we have shown that ER activation by E 2 caused an induction of BCA2 mRNA and protein expression levels in the ER-positive MCF7 breast cancer line and MDA MB 231/ER stably transfected cell line. Consistent with this, treatment of these cells with ER antagonists ICI and tamoxifen significantly decreased the BCA2 expression levels. Confocal microscopy suggested that E 2 induced a relatively significant BCA2 signal in both the cytoplasm and nucleus. When hormone-depleted MCF7 cells were treated with ER siRNA, the knockdown caused a significant decrease (about 63 %) in BCA2 protein levels and its localization was limited to the cytoplasm and nuclear membrane regions. Interestingly, genome wide ER-binding studies suggest that the promoter region of BCA2 consists of an ER-binding peak detected upon induction. Bioinformatics studies of the BCA2 promoter revealed four ERE half sites in the proximal promoter region. BCA2 promoter luciferase assays confirmed the role of ER in BCA2 promoter activation. ER antagonists clearly showed inhibitory effects in the reporter assays in all of the cell lines tested, either with endogenous ER or exogenously transfected ER. The specificity of BCA2 promoter response to E 2 is demonstrated by the lack of reporter activity in its absence. The E 2 induced reporter activity was reduced to the basal level with excess of tamoxifen used to treat ER-positive breast cancer patients [41, 42] . Recruitment of ER to the BCA2 promoter with E 2 induction in our ChIP analysis is direct evidence of ER activation of the BCA2 gene, but further analysis of the exact factors involved in this molecular mechanism have yet to be established. We also found the transcriptional regulation of BCA2 by ER in another ER-positive cell line T47D (data not shown). Although the basal transcription of this gene may also be regulated by other transcription factors, especially in ER-negative cell lines, all of the experimental evidence discussed in this article confirms that BCA2 is an ER-regulated gene at least in the ERpositive MCF7 breast cancer cell line. More work is needed to extend this study to many other ER-positive breast cancer cell lines and tissues.
BCA2 is an E3 ligase whose activity might be important for the ubiquitination of proteins essential in the pathogenesis of breast cancer. BCA2 expression correlates with ER status in breast cancer patients and is predicted to be oncogenic in hormone-dependent breast cancers. Therefore, the mechanism by which BCA2 is regulated might be important in the understanding of breast cancer development and metastasis. Thus, targeting BCA2 ligase activity with small molecule inhibitors may be useful in the inhibition of breast cancer development and progression.
